Lercanidipine in Patients with Chronic Renal Failure: The ZAFRA Study

Autor:	J. Villatoro, B. Rincon, J. Torrijos, Niclás Roberto Robles, M Manjon, M. M. A. Rodriguez, Francisco Martínez, A. Liebana, Jesus Marco, Julio Herrera, J Calls, L Pastor, C F. Gomez, M. L. Mendez, A Morey, V. I. Rodríguez, F. Tornero, J. Ocon
Rok vydání:	2005
Předmět:	Nephrology medicine.medical_specialty hypertension medicine.drug_class Urology Renal function Calcium channel blocker Urine Critical Care and Intensive Care Medicine chemistry.chemical_compound chronic renal failure Internal medicine medicine Diseases of the circulatory (Cardiovascular) system Creatinine business.industry Lercanidipine lercanidipine General Medicine medicine.disease Endocrinology Blood pressure chemistry RC666-701 business Kidney disease medicine.drug
Zdroj:	Кардиоваскулярная терапия и профилактика, Vol 9, Iss 4, Pp 81-87 (2010)
ISSN:	0886-022X
DOI:	10.1081/jdi-200042801
Popis:	Aim. To evaluate the safe use of a new calcium channel blocker, lercanidipine, in patients with chronic renal failure (CRF); the protective effect of calcium channel blocker on renal function in CRF patients previously treated with ACE inhibitors or angiotensin receptor blockers (ARB). Material and methods. The study included 203 CRF patients (creatinine >1,4 mg/dL for men, >1,2 mg/dL for women; or creatinine clearance
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04cd7ffa8e9e254b26a7e9429060f3ad https://doi.org/10.1081/jdi-200042801 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.